Search

Your search keyword '"Verma, Sunil"' showing total 448 results
Start Over Author "Verma, Sunil" Search Limiters Full Text
448 results on '"Verma, Sunil"'

1. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

Author

Harbeck, Nadia, Ciruelos, Eva, Jerusalem, Guy, Müller, Volkmar, Niikura, Naoki, Viale, Giuseppe, Bartsch, Rupert, Kurzeder, Christian, Higgins, Michaela J., Connolly, Roisin M., Baron-Hay, Sally, Gión, María, Guarneri, Valentina, Bianchini, Giampaolo, Wildiers, Hans, Escrivá-de-Romaní, Santiago, Prahladan, Manoj, Bridge, Helen, Kuptsova-Clarkson, Nataliya, Scotto, Nana, Verma, Sunil, and Lin, Nancy U.

Published
2024
Full Text
View/download PDF

7. Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

Author

Harbeck, Nadia, Ciruelos, Eva, Jerusalem, Guy, Müller, Volkmar, Niikura, Naoki, Viale, Giuseppe, Bartsch, Rupert, Kurzeder, Christian, Higgins, Michaela J., Connolly, Roisin M., Baron-Hay, Sally, Gión, María, Guarneri, Valentina, Bianchini, Giampaolo, Wildiers, Hans, Escrivá-de-Romaní, Santiago, Prahladan, Manoj, Bridge, Helen, Kuptsova-Clarkson, Nataliya, Scotto, Nana, Verma, Sunil, and Lin, Nancy U.

Published
2024
Full Text
View/download PDF

8. Magnetotransport Properties and Fermi Surface Topology of Nodal line Semimetal InBi

Author

Dan, Sambhab, Kargeti, Kuldeep, Sahoo, R. C., Dan, Shovan, Pal, Debarati, Verma, Sunil, Chakravarty, Sujay, Panda, S. K., and Patil, S

Subjects
Condensed Matter - Materials Science
Abstract

In the present study, we have discussed the up-turn behavior in the resistivity pattern of the topological nodal line semimetal InBi. We argued that such nature could be generalized with a mathematical model, that can be applied to any compounds exhibiting similar behavior. The extremely high magnetoresistance (XMR) has also been explained by the carrier compensation in the compound, estimated from the Hall conductivity. Moreover, from the study of Subhnikov-de Haas (SdH) oscillation and density functional theory (DFT), we obtained the complete three-dimensional (3D) Fermi surface topology of the compound InBi. A detailed understanding of carriers' behavior has been discussed using those studies. We have also unfurled the topology of each electron and hole pocket and its possible modulation with electron and hole doping.

Published
2022
Full Text
View/download PDF

13. Association of Social Determinants of Health with Time to Diagnosis and Treatment Outcomes in Idiopathic Subglottic Stenosis.

Author

Lee, Jaclyn, Huang, Li-Ching, Berry, Lynn, Anderson, Catherine, Amin, Milan, Benninger, Michael, Blumin, Joel, Bock, Jonathan, Bryson, Paul, Castellanos, Paul, Chen, Sheau-Chiann, Clary, Matthew, Cohen, Seth, Crawley, Brianna, Dailey, Seth, Daniero, James, de Alarcon, Alessandro, Donovan, Donald, Edell, Eric, Ekbom, Dale, Fink, Daniel, Franco, Ramon, Garrett, C, Guardiani, Elizabeth, Hillel, Alexander, Hoffman, Henry, Hogikyan, Norman, Howell, Rebecca, Hussain, Lena, Johns, Michael, Kasperbauer, Jan, Khosla, Sid, Kinnard, Cheryl, Kupfer, Robbi, Langerman, Alexander, Lentz, Robert, Lorenz, Robert, Lott, David, Lowery, Anne, Makani, Samir, Maldonado, Fabien, Mannion, Kyle, Matrka, Laura, McWhorter, Andrew, Merati, Albert, Mori, Matthew, Netterville, James, ODell, Karla, Ongkasuwan, Julina, Postma, Gregory, Reder, Lindsay, Rohde, Sarah, Richardson, Brent, Rickman, Otis, Rosen, Clark, Rutter, Michael, Sandhu, Guri, Schindler, Joshua, Schneider, G, Shah, Rupali, Sikora, Andrew, Sinard, Robert, Smith, Marshall, Smith, Libby, Soliman, Ahmed, Sveinsdóttir, Sigríður, Van Daele, Douglas, Veivers, David, Verma, Sunil, Weinberger, Paul, Wootten, Christopher, Shyr, Yu, Francis, David, Gelbard, Alexander, and Weissbrod, Philip

Subjects
education, iSGS, income, social support, surgical outcomes, time to diagnosis, Adult, Female, Follow-Up Studies, Humans, Laryngoscopy, Laryngostenosis, Male, Middle Aged, Prospective Studies, Recurrence, Social Determinants of Health, Time Factors, Treatment Outcome, United States
Abstract

OBJECTIVES: To examine whether social determinants of health (SDH) factors are associated with time to diagnosis, treatment selection, and time to recurrent surgical intervention in idiopathic subglottic stenosis (iSGS) patients. METHODS: Adult patients with diagnosed iSGS were recruited prospectively (2015-2017) via clinical providers as part of the North American Airway Collaborative (NoAAC) and via an online iSGS support community on Facebook. Patient-specific SDH factors included highest educational attainment (self-reported), median household income (matched from home zip code via U.S. Census data), and number of close friends (self-reported) as a measure of social support. Main outcomes of interest were time to disease diagnosis (years from symptom onset), treatment selection (endoscopic dilation [ED] vs cricotracheal resection [CTR] vs endoscopic resection with adjuvant medical therapy [ERMT]), and time to recurrent surgical intervention (number of days from initial surgical procedure) as a surrogate for disease recurrence. RESULTS: The total 810 participants were 98.5% female, 97.2% Caucasian, and had a median age of 50 years (IQR, 43-58). The cohort had a median household income of $62 307 (IQR, $50 345-$79 773), a median of 7 close friends (IQR, 4-10), and 64.7% of patients completed college or graduate school. Education, income, and number of friends were not associated with time to diagnosis via multivariable linear regression modeling. Univariable multinominal logistic regression demonstrated an association between education and income for selecting ED versus ERMT, but no associations were noted for CTR. No associations were noted for time to recurrent surgical procedure via Kaplan Meier modeling and Cox proportional hazards regression. CONCLUSIONS: Patient education, income, and social support were not associated with time to diagnosis or time to disease recurrence. This suggests additional patient, procedure, or disease-specific factors contribute to the observed variations in iSGS surgical outcomes.

Published
2021

17. Surface kinematic and depth-resolved analysis of human vocal folds in vivo during phonation using optical coherence tomography.

Author

Sharma, Giriraj K, Chen, Lily Y, Chou, Lidek, Badger, Christopher, Hong, Ellen, Rangarajan, Swathi, Chang, Theodore H, Armstrong, William B, Verma, Sunil P, Chen, Zhongping, Ramalingam, Ram, and Wong, Brian J-F

Subjects
image processing, in vivo imaging, larynx, mucosal wave, optical coherence tomography, tissues, Optics, Optical Physics, Biomedical Engineering, Opthalmology and Optometry
Abstract

SignificanceThe human vocal fold (VF) oscillates in multiple vectors and consists of distinct layers with varying viscoelastic properties that contribute to the mucosal wave. Office-based and operative laryngeal endoscopy are limited to diagnostic evaluation of the VF epithelial surface only and are restricted to axial-plane characterization of the horizontal mucosal wave. As such, understanding of the biomechanics of human VF motion remains limited.AimOptical coherence tomography (OCT) is a micrometer-resolution, high-speed endoscopic imaging modality which acquires cross-sectional images of tissue. Our study aimed to leverage OCT technology and develop quantitative methods for analyzing the anatomy and kinematics of in vivo VF motion in the coronal plane.ApproachA custom handheld laryngeal stage was used to capture OCT images with 800 A-lines at 250 Hz. Automated image postprocessing and analytical methods were developed.ResultsNovel kinematic analysis of in vivo, long-range OCT imaging of the vibrating VF in awake human subjects is reported. Cross-sectional, coronal-plane panoramic videos of the larynx during phonation are presented with three-dimensional videokymographic and space-time velocity analysis of VF motion.ConclusionsLong-range OCT with automated computational methods allows for cross-sectional dynamic laryngeal imaging and has the potential to broaden our understanding of human VF biomechanics and sound production.

Published
2021

18. Impact of the 2017 ACC/AHA guidelines on the prevalence of hypertension among Indian adults: Results from a cross-sectional survey

Author

Gupta, Kartik, Ramakrishnan, Sivasubramanian, Zachariah, Geevar, Rao, J Shivkumar, Mohanan, PP, Venugopal, K, Sateesh, Santosh, Sethi, Rishi, Jain, Dharmendra, Bardolei, Neil, Mani, Kalaivani, Kakar, Tanya Singh, Jain, Vardhmaan, Gupta, Prakash, Gupta, Rajeev, Bansal, Sandeep, Nath, Ranjit K, Tyagi, Sanjay, Wander, GS, Gupta, Satish, Mandal, Subroto, Senguttuvan, Nagendra Boopathy, Subramanyam, Geetha, Roy, Debabatra, Datta, Sibananda, Ganguly, Kajal, Routray, SN, Mishra, SS, Singh, BP, Bharti, BB, Das, Mrinal Kanti, Deb, PK, Deedwania, Prakash, Seth, Ashok, Sinha, AK, Bhushan, Sudha, Verma, Sunil K, Bhargava, Balram, Roy, Ambuj, Sood, Sanjay, Isser, HS, Pandit, Neeraj, Trehan, Vijay, Gupta, Mohit D, Girish, MP, Ahuja, Ramandeep, Manchanda, SC, Mohanty, Arun, Jain, Peeyush, Shrivastava, Sameer, Kalra, IPS, Sarang, BS, Ratti, HS, Sahib, G Bala, Gupta, Rakesh, Amit, SK Agarwal, Goswami, KC, Bahl, VK, Chopra, HK, Koshy, George, Nair, Tiny, Shyam, N, Roby, Anil, George, Raju, Kumar, Sudhaya, Kader, Abdul, Abraham, Mathew, Viswanathan, Sunitha, Jabir, A, Menon, Jaideep, Unni, Govindan, Mathew, Cibu, Jayagopal, PB, Sajeev, Ashokan, PK, Asharaf, Pancholia, AK, Gupta, AK, Das, Rupam, Aggarwal, Dinesh, Malviya, Amit, Ali, Syed Manzor, and Barward, Parag

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Prevention, Cardiovascular, Hypertension, ACC/AHA blood Pressure guideline, Prevalence, India, Health policy, CSI-Great India BP Campaign Investigators, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

BackgroundThe impact of the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for diagnosis and management of hypertension on the prevalence of hypertension in India is unknown.MethodsWe analyzed data from the Cardiac Prevent 2015 survey to estimate the change in the prevalence of hypertension. The JNC8 guidelines defined hypertension as a systolic blood pressure of ≥140 ​mmHg or diastolic blood pressure of ≥90 ​mmHg. The 2017 ACC/AHA guidelines define hypertension as a systolic blood pressure of ≥130 ​mmHg or diastolic blood pressure of ≥80 ​mmHg. We standardized the prevalence as per the 2011 census population of India. We also calculated the prevalence as per the World Health Organization (WHO) World Standard Population (2000-2025).ResultsAmong 180,335 participants (33.2% women), the mean age was 40.6 ​± ​14.9 years (41.1 ​± ​15.0 and 39.7 ​± ​14.7 years in men and women, respectively). Among them, 8,898 (4.9%), 99,791 (55.3%), 35,694 (11.9%), 23,084 (12.8%), 9,989 (5.5%) and 2,878 (1.6%) participants belonged to age group 18-19, 20-44, 45-54, 55-64, 65-74 and ​≥ ​75 years respectively. The prevalence of hypertension according to the JNC8 and 2017 ACC/AHA guidelines was 29.7% and 63.8%, respectively- an increase of 115%. With the 2011 census population of India, this suggests that currently, 486 million Indian adults have hypertension according to the 2017 ACC/AHA guidelines, an addition of 260 million as compared to the JNC8 guidelines.ConclusionAccording to the 2017 ACC/AHA guidelines, 3 in every 5 Indian adults have hypertension.

Published
2020

20. Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.

Author

Diéras, Véronique, Harbeck, Nadia, Joy, Anil Abraham, Gelmon, Karen, Ettl, Johannes, Verma, Sunil, Lu, Dongrui R, Gauthier, Eric, Schnell, Patrick, Mori, Ave, Rugo, Hope S, and Finn, Richard S

Subjects
Humans, Breast Neoplasms, Piperazines, Pyridines, Receptor, erbB-2, Antineoplastic Combined Chemotherapy Protocols, Postmenopause, Female, Letrozole, Breast cancer, Hematologic, Neutropenia, Palbociclib, Safety, Receptor, ErbB-2, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundPALOMA-2 confirmed that first-line palbociclib + letrozole improved progression-free survival (hazard ratio, 0.58; 95% confidence interval, 0.46-0.72) in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). This analysis evaluated palbociclib-associated hematologic adverse events (AEs) and provides insight on managing these AEs.Materials and methodsPostmenopausal women with ER+/HER2- ABC were randomly assigned 2:1 to letrozole (2.5 mg daily continuously) plus oral palbociclib (125 mg daily; 3 weeks on/1 week off) or placebo. Safety assessments were performed at baseline, days 1 and 15 (first two cycles) and day 1 of subsequent cycles, and included white blood cell, platelet, and absolute neutrophil count (ANC).ResultsPALOMA-2 randomized 666 women to palbociclib + letrozole (n = 444) or placebo + letrozole (n = 222). Neutropenia was the most common AE (95.3%) with palbociclib (grade 3, 55.6%; grade 4, 11.5%) and was managed by dose modifications; progression-free survival was similar between patients who experienced grade ≥ 3 neutropenia versus those who did not. Median (range) time to onset of neutropenia with palbociclib + letrozole was 15 (12-700) days (grade ≥ 3, 28.0 [12-854] days); median duration of each neutropenia episode grade ≥ 3 was 7.0 days. Asian ethnicity and low baseline ANC were associated with increased risk of grade 3/4 neutropenia with palbociclib (p < .001).ConclusionPalbociclib + letrozole was generally well tolerated. Neutropenia, the most frequently reported AE in women with ER+/HER2- ABC, was mostly transient and manageable by dose modifications in patients who experienced grade ≥ 3 neutropenia, without appearing to compromise efficacy. (Pfizer; NCT01740427) IMPLICATIONS FOR PRACTICE: Palbociclib demonstrated an acceptable safety profile in PALOMA-2 in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) receiving first-line palbociclib + letrozole. Although hematologic adverse events (AEs) are typically expected with anticancer therapies and are often clinically significant, palbociclib-related hematologic AEs, particularly neutropenia (most frequent AE), were transient/manageable by dose reduction, interruption, or cycle delay, which is in contrast to the more profound neutropenia associated with chemotherapy. Palbociclib dose adjustments decreased hematologic AE severity without appearing to compromise efficacy, supporting palbociclib + letrozole as a first-line treatment for ER+/HER2- ABC.

Published
2019

21. Safety of outpatient unilateral medialization laryngoplasty across two academic institutions

Author

Chau, Steven M, Kim, Christine M, Vahabzadeh‐Hagh, Andrew, Verma, Sunil P, and Chhetri, Dinesh K

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Patient Safety, 6.4 Surgery, Evaluation of treatments and therapeutic interventions, Academic Medical Centers, Ambulatory Surgical Procedures, Dimethylpolysiloxanes, Dysphonia, Female, Glottis, Humans, Incidence, Laryngoplasty, Male, Middle Aged, Polytetrafluoroethylene, Postoperative Complications, Prostheses and Implants, Reoperation, Retrospective Studies, Treatment Outcome, Unilateral vocal fold paralysis, medialization, laryngoplasty, ambulatory, Otorhinolaryngology, Clinical sciences
Abstract

Objectives/hypothesisUnilateral ML is a commonly performed surgery for dysphonia secondary to glottic insufficiency. The safety of this procedure performed in the outpatient setting has not been extensively examined. The purpose of the study was to assess the safety of outpatient unilateral ML in adults and determine the incidence and timing of postoperative complications across two tertiary-care academic medical centers.Study designRetrospective chart review, METHODS: A review of patients undergoing unilateral ML at two tertiary-care academic centers from 2011 to 2017 was performed. Patients undergoing bilateral medialization laryngoplasty, revision surgery, or those undergoing additional laryngeal framework procedures including arytenoid adduction were excluded. Patient demographics, operative details, and perioperative and postoperative complications were recorded. Comparisons were made between those individuals who underwent inpatient versus outpatient ML.ResultsOne hundred three total procedures met inclusion criteria. Fifty-seven were performed as outpatient procedures, and 46 individuals were observed for at least 23 hours following surgery. Silastic or Gore-Tex implants were used in all but two surgeries. There were no postoperative complications in either setting, including hematoma, dyspnea, wound infections or seromas.ConclusionsThe incidence of adverse events during and immediately following unilateral ML is very low. Patients can be discharged safely the day of surgery without geographic restrictions.Level of evidence4 Laryngoscope, 129:1647-1649, 2019.

Published
2019

23. Mitotic spindle due to posterior capsular opacification

Author

Bhayana, Amber, Nyodu, Richa, Verma, Sunil, and Sharma, Bhavana

Subjects
Health
Abstract

Byline: Amber. Bhayana, Richa. Nyodu, Sunil. Verma, Bhavana. Sharma Posterior capsular opacification was incidentally noted in a 65-year-old, otherwise healthy pseudophakic male. There were two foci of the same which [...]

Published
2023

24. Selective recurrent laryngeal nerve stimulation using a penetrating electrode array in the feline model.

Author

Haidar, Yarah M, Sahyouni, Ronald, Moshtaghi, Omid, Wang, Beverly Y, Djalilian, Hamid R, Middlebrooks, John C, Verma, Sunil P, and Lin, Harrison W

Subjects
Laryngeal Muscles, Nerve Fibers, Recurrent Laryngeal Nerve, Animals, Cats, Vocal Cord Paralysis, Disease Models, Animal, Electromyography, Electric Stimulation Therapy, Electric Stimulation, Electrodes, Implanted, Muscle Contraction, Recurrent Laryngeal Nerve Injuries, Recurrent laryngeal nerve, multichannel electrode array, posterior cricoarytenoid, posterior cricoarytenoid muscle, recurrent laryngeal nerve implant, recurrent laryngeal nerve stimulation, Neurodegenerative, Neurosciences, multi-channel electrode array, Clinical Sciences, Otorhinolaryngology
Abstract

OBJECTIVES/HYPOTHESIS:Laryngeal muscles (LMs) are controlled by the recurrent laryngeal nerve (RLN), injury of which can result in vocal fold (VF) paralysis (VFP). We aimed to introduce a bioelectric approach to selective stimulation of LMs and graded muscle contraction responses. STUDY DESIGN:Acute experiments in cats. METHODS:The study included six anesthetized cats. In four cats, a multichannel penetrating microelectrode array (MEA) was placed into an uninjured RLN. For RLN injury experiments, one cat received a standardized hemostat-crush injury, and one cat received a transection-reapproximation injury 4 months prior to testing. In each experiment, three LMs (thyroarytenoid, posterior cricoarytenoid, and cricothyroid muscles) were monitored with an electromyographic (EMG) nerve integrity monitoring system. Electrical current pulses were delivered to each stimulating channel individually. Elicited EMG voltage outputs were recorded for each muscle. Direct videolaryngoscopy was performed for visualization of VF movement. RESULTS:Stimulation through individual channels led to selective activation of restricted nerve populations, resulting in selective contraction of individual LMs. Increasing current levels resulted in rising EMG voltage responses. Typically, activation of individual muscles was successfully achieved via single placement of the MEA by selection of appropriate stimulation channels. VF abduction was predominantly observed on videolaryngoscopy. Nerve histology confirmed injury in cases of RLN crush and transection experiments. CONCLUSIONS:We demonstrated the ability of a penetrating MEA to selectively stimulate restricted fiber populations within the feline RLN and selectively elicit contractions of discrete LMs in both acute and injury-model experiments, suggesting a potential role for intraneural MEA implantation in VFP management. LEVEL OF EVIDENCE:NA. Laryngoscope, 128:1606-1614, 2018.

Published
2018

27. Idiopathic Subglottic Stenosis in Non‐Caucasian Women.

Author

Suk, Amber, Dehom, Salem, Punjabi, Nihal, Young, VyVy N., Krishna, Priya D., Reder, Lindsay, O'Dell, Karla, Gochman, Grant E., Simmons, Ethan, Verma, Sunil P., Harmon, Matthew, Weissbrod, Philip A., Yang, Jin, Tamares, Shanalee, and Crawley, Brianna K.

Published
2024
Full Text
View/download PDF

28. Impact of the 2017 ACC/AHA guidelines on the prevalence of hypertension among Indian adults: Results from a cross-sectional survey

Author

Shivkumar Rao, J., Singh, B.P., Bharti, B.B., Sinha, A.K., Gupta, Kartik, Ramakrishnan, Sivasubramanian, Bhushan, Sudha, Verma, Sunil K., Bhargava, Balram, Roy, Ambuj, Bansal, Sandeep, Sood, Sanjay, Isser, H.S., Pandit, Neeraj, Nath, Ranjit K., Tyagi, Sanjay, Trehan, Vijay, Gupta, Mohit D., Girish, M.P., Ahuja, Ramandeep, Manchanda, S.C., Mohanty, Arun, Jain, Peeyush, Shrivastava, Sameer, Kalra, I.P.S., Sarang, B.S., Ratti, H.S., Sahib, G. Bala, Gupta, Rakesh, Amit, S K Agarwal, Goswami, K.C., Bahl, V.K., Chopra, H.K., Seth, Ashok, Zachariah, Geevar, Mohanan, P.P., Venugopal, K., Koshy, George, Nair, Tiny, Shyam, N., Roby, Anil, George, Raju, Kumar, Sudhaya, Kader, Abdul, Abraham, Mathew, Viswanathan, Sunitha, Jabir, A., Menon, Jaideep, Unni, Govindan, Mathew, Cibu, Jayagopal, P.B., Sajeev, Ashokan, P.K., Asharaf, Mandal, Subroto, Pancholia, A.K., Bardolei, Neil, Gupta, A.K., Das, Rupam, Aggarwal, Dinesh, Malviya, Amit, Routray, S.N., Mishra, S.S., Ali, Syed Manzor, Barward, Parag, Singh, Navreet, Tomar, Yashbir S., Chaddha, Davinder, Dani, Sameer, Vyas, Chirayu, Bhatt, Kinjal, Doshi, Shrenik, Wander, G.S., Gupta, Satish, Meena, Chandra Bhan, Sateesh, Santosh, Senguttuvan, Nagendra Boopathy, Subramanyam, Geetha, Subramanyam, Muruganandam, Ajit Mullasari, Sethi, Rishi, Narain, Varun, Saran, R.K., Jain, Dharmendra, Jain, Praveen, Kumar, Sudeep, Goel, P.K., Roy, Debabatra, Datta, Sibananda, Ganguly, Kajal, Das, M.K., Kumar, Soumitra, Chandra, Sarat, Banerjee, Amal, Guha, Santanu, Deb, P.K., Rao, J. Shivkumar, Mani, Kalaivani, Kakar, Tanya Singh, Jain, Vardhmaan, Gupta, Prakash, Gupta, Rajeev, Das, Mrinal Kanti, and Deedwania, Prakash

Published
2020
Full Text
View/download PDF

29. Sex Differences in Revascularization, Treatment Goals, and Outcomes of Patients With Chronic Coronary Disease: Insights From the ISCHEMIA Trial

Author

Reynolds, Harmony R., primary, Cyr, Derek D., additional, Merz, C. Noel Bairey, additional, Shaw, Leslee J., additional, Chaitman, Bernard R., additional, Boden, William E., additional, Alexander, Karen P., additional, Rosenberg, Yves D., additional, Bangalore, Sripal, additional, Stone, Gregg W., additional, Held, Claes, additional, Spertus, John, additional, Goetschalckx, Kaatje, additional, Bockeria, Olga, additional, Newman, Jonathan D., additional, Berger, Jeffrey S., additional, Elghamaz, Ahmed, additional, Lopes, Renato D., additional, Min, James K., additional, Berman, Daniel S., additional, Picard, Michael H., additional, Kwong, Raymond Y., additional, Harrington, Robert A., additional, Thomas, Boban, additional, O'Brien, Sean M., additional, Maron, David J., additional, Hochman, Judith S., additional, Mavromatis, Kreton, additional, Linefsky, Jason, additional, Miller, Todd, additional, Banerjee, Subhash, additional, Reynolds, Harmony R., additional, Donnino, Robert M., additional, Phillips, Lawrence M., additional, Saric, Muhamed, additional, Abdul‐Nour, Khaled, additional, Stone, Peter H., additional, Jang, James J., additional, Yee, Gennie, additional, Weitz, Steven, additional, Arnold, Suzanne, additional, O’Keefe, James Henry, additional, Shapiro, Michael D., additional, El‐Hajjar, Mohammad, additional, Sidhu, Mandeep S., additional, Fein, Steven A., additional, Torosoff, Mikhail T., additional, Lyubarova, Radmila, additional, Mookherjee, Sulagna, additional, Drzymalski, Krzysztof, additional, McFalls, Edward O., additional, Garcia, Santiago A., additional, Bertog, Stefan C., additional, Siddiqui, Rizwan A., additional, Ishani, Areef, additional, Hansen, Ronnell A., additional, Khouri, Michel Georges, additional, Goldberg, Jonathan L., additional, Goldweit, Richard, additional, Cohen, Ronny A., additional, Mirrer, Brooks, additional, Navarro, Victor, additional, Winchester, David E., additional, Kronenberg, Marvin, additional, Rogal, Philip, additional, McFarren, Christopher, additional, Heitner, John F., additional, Dauber, Ira M., additional, Cannan, Charles, additional, Sudarshan, Sriram, additional, Mehta, Puja K., additional, McDaniel, Michael, additional, Lerakis, Stamatios, additional, Quyyumi, Arshed, additional, Wenger, Nanette K., additional, Hedgepeth, Chester M., additional, Hurlburt, Heather, additional, Rosen, Alan, additional, Sahul, Zakir, additional, Booth, David, additional, Leung, Steve, additional, Abdel‐Latif, Ahmed, additional, Reda, Hassan, additional, Ziada, Khaled, additional, Setty, Sampoornima, additional, Barua, Rajat S., additional, Hage, Fadi, additional, Caldeira, Christiano, additional, Davies, James E., additional, Leesar, Massoud, additional, Heo, Jaekyeong, additional, Iskandrian, Amy, additional, Al Solaiman, Firas, additional, Singh, Satinder, additional, Dajani, Khaled, additional, Der Mesropian, Paul, additional, Sacco, Joseph, additional, McCandless, Brian, additional, Orgera, Marisa, additional, Arif, Imran, additional, Kerr, Hanan, additional, Trejo (Gutierrez), Jorge F., additional, Fletcher, Gerald, additional, Lane, Gary E., additional, Neeson, Lynn M., additional, Parikh, Pragnesh P., additional, Pollak, Peter M., additional, Shapiro, Brian P., additional, Landolfo, Kevin, additional, Gemignani, Anthony, additional, O’Rourke, Daniel, additional, Meadows, Judith L., additional, Call, Jason T., additional, Hannan, Joseph, additional, Bojar, Robert, additional, Kumar, Deepti, additional, Mukai, John, additional, Martin, Edward T., additional, Vorobiof, Gabriel, additional, Moorman, Alec, additional, Kinlay, Scott, additional, Hamburger, Robert J., additional, Rocco, Thomas P., additional, Bhatt, Deepak L., additional, Croce, Kevin, additional, Quin, Jacquelyn A., additional, Anumpa, Jati, additional, Zenati, Marco, additional, Faxon, David P., additional, Rayos, Glenn, additional, Seedhom, Ashraf, additional, Sullenberger, Lance, additional, Kumkumian, Gregory, additional, Sedlis, Steven P., additional, Donnino, Robert M., additional, Lorin, Jeffrey, additional, Tamis‐Holland, Jacqueline E., additional, Kornberg, Robert, additional, Leber, Robert, additional, Saba, Souheil, additional, Lee, Michael W., additional, Small, Delano R., additional, Nona, Wassim, additional, Alexander, Patrick B., additional, Rehman, Iram, additional, Badami, Umesh, additional, Marzo, Kevin, additional, Robbins, Inga H., additional, Levite, Howard A., additional, Shetty, Sanjay, additional, Patel, Mayuri, additional, Hamroff, Glenn S., additional, Little, Raymond W., additional, Zimbelman, Brandi D., additional, Lui, Charles Y., additional, Smith, Brigham R., additional, Vezina, Daniel P., additional, Khor, Lillian L., additional, Abraham, Josephine D., additional, Bull, David A., additional, McKellar, Stephen H., additional, Kotter, John, additional, Hu, Bob, additional, Labovitz, Arthur J., additional, Berlowitz, Michael, additional, Matar, Fadi, additional, Rodriguez, Fatima, additional, Schnittger, Ingela, additional, Fearon, William F., additional, Deedwania, Prakash, additional, Reddy, Kiran, additional, Sweeny, Joseph, additional, Spizzieri, Christopher, additional, Hochberg, Claudia P., additional, Salerno, William D., additional, Wyman, Ray, additional, Zarka, Amer, additional, Shah, Anil V., additional, Haldis, Thomas, additional, Kohn, Jeffrey A., additional, Girotra, Saket, additional, Almousalli, Omar, additional, Krishnam, Mayil S., additional, Milliken, Jeffrey C., additional, Patel, Pranav M., additional, Seto, Arnold H., additional, Harley, Kevin T., additional, Gibson, Michael A., additional, Allen, Byron J., additional, Coram, Rita, additional, Thomas, Sabu, additional, Schwartz, Ronald G., additional, Chen, Wei, additional, El Shahawy, Mahfouz, additional, Stafford, James, additional, Abernethy, William B., additional, Zurick, Andrew, additional, Meyer, Thomas M., additional, Morford, Ronald G., additional, Rutkin, Bruce, additional, Bokhari, Sabahat, additional, Sokol, Seth I., additional, Meisner, Jay, additional, Hamzeh, Ihab, additional, Misra, Arunima, additional, Wall, Matthew, additional, De Rosen, Veronica Lenges, additional, Alam, Mahboob, additional, Turner, Michael C., additional, Mulhearn, Thomas J., additional, Good, Arnold P., additional, Shammas, Nicolas W., additional, Chilton, Robert, additional, Nguyen, Patricia K., additional, Jezior, Matthew, additional, Gordon, Paul C., additional, Crain, Thomas, additional, Stenberg, Robert, additional, Pedalino, Ronald P., additional, Wiesel, Joseph, additional, Juang, George J., additional, Al‐Amoodi, Mohammed, additional, Wohns, David, additional, Lader, Ellis W., additional, Mumma, Michael, additional, Dharmarajan, Lekshmi, additional, McGarvey, Joseph F. X., additional, Downes, Thomas R., additional, Luckasen, Gary J., additional, Cheong, Benjamin, additional, Potluri, Srinivasa, additional, Mastouri, Ronald A., additional, Breall, Jeffery A., additional, Revtyak, George E., additional, Bazeley, Jonathan W., additional, Li, Dayuan, additional, Giedd, Kenneth, additional, Old, Wayne, additional, Burt, Francis, additional, Sokhon, Kozhaya, additional, Gopal, Deepika, additional, Valeti, Uma S., additional, Kobashigawa, Jon, additional, Govindan, Sajeev Chakanalil, additional, Nair, Rajesh Gopalan, additional, Manjunath, Cholenahally Nanjappa, additional, Moorthy, Nagaraja, additional, Manjunath, Satvic Cholenahally, additional, Narayanappa, Suryaprakash, additional, Pandit, Neeraj, additional, Nath, Ranjit Kumar, additional, Dwivedi, S. K., additional, Narain, V. S., additional, Chandra, Sharad, additional, Wander, Gurpreet S., additional, Tandon, Rohit, additional, Ralhan, Sarju, additional, Aslam, Naved, additional, Goyal, Abhishek, additional, Bhargava, Balram, additional, Karthikeyan, G., additional, Ramakrishnan, S., additional, Seth, Sandeep, additional, Yadav, Rakesh, additional, Singh, Sandeep, additional, Roy, Ambuj, additional, Parakh, Neeraj, additional, Verma, Sunil Kumar, additional, Narang, Rajiv, additional, Mishra, Sundeep, additional, Naik, Nitish, additional, Sharma, Gautam, additional, Choudhary, Shiv Kumar, additional, Patel, Chetan, additional, Gulati, Gurpreet, additional, Sharma, Sanjeev, additional, Bahl, V. K., additional, Mathew, Anoop, additional, Punnoose, Eapen, additional, Gadkari, Milind Avdhoot, additional, Gadage, Siddharth, additional, Pillay, Tapan Umesh, additional, Satheesh, Santhosh, additional, Mathur, Atul, additional, Kaul, Upendra, additional, Christopher, Johann, additional, Menon, Rajeev, additional, Kumar, Nirmal, additional, Oomman, Abraham, additional, Mao, Robert, additional, Solomon, Hilda, additional, Naik, Sudhir, additional, Khan, Sajeeda Parveen, additional, Grant, Purvez, additional, Kachru, Ranjan, additional, Ajit Kumar, V. K., additional, Ganapathi, Sanjay, additional, Jayakumar, K., additional, Sivadasanpillai, Harikrishnan, additional, Sasidharan, Bijulal, additional, Kapilamoorthy, T. R., additional, Polamuri, Praneeth, additional, Senior, Roxy, additional, Gurunathan, Sothinathan, additional, Karogiannis, Nikolaos, additional, Shah, Benoy N., additional, Trimlett, Richard HJ, additional, Rubens, Michael B., additional, Nicol, Edward D., additional, Mittal, Tarun K., additional, Hampson, Reinette, additional, Gamma, Reto Andreas, additional, de Belder, Mark A., additional, Thambyrajah, Jeet, additional, Nageh, Thuraia, additional, Davies, John R., additional, Lindsay, Steven J., additional, Kurian, John, additional, Jamil, Haqeel, additional, Raheem, Osama, additional, Hoye, Angela, additional, Donnelly, Patrick, additional, Valecka, Bernardas, additional, Chauhan, Anoop, additional, Barr, Craig, additional, Alfakih, Khaled, additional, Byrne, Jonathan, additional, Webb, Ian, additional, Henriksen, Peter, additional, OKane, Peter, additional, de Silva, Ramesh, additional, Conway, Dwayne S. G., additional, Sirker, Alexander A, additional, Hoole, Stephen P., additional, Witherow, Fraser N., additional, Johnston, Nicola, additional, Harbinson, Mark, additional, Walsh, Simon, additional, Douglas, Hanna, additional, Luckie, Matthew, additional, Sobolewska, Jolanta, additional, Jeetley, Paramjit, additional, Patel, Niket, additional, Kotecha, Tushar, additional, Travill, Christopher, additional, Karimullah, Iqbal, additional, Al‐Bustami, Mahmud, additional, Braganza, Denise, additional, Henderson, Robert, additional, Pointon, Kate, additional, Naik, Surendra, additional, Mathew, Thomas, additional, Berry, Colin, additional, Collison, Damien, additional, Roditi, Giles, additional, Moriarty, Andrew J., additional, Glover, Jason D., additional, Pradhan, Jiwan, additional, Mikhail, Ghada, additional, Francis, Darrel P., additional, Gosselin, Gilbert, additional, Diaz, Ariel, additional, Rheault, Philippe, additional, Barrero, Miguel, additional, Gagné, Carl‐Éric, additional, Pépin‐Dubois, Yanek, additional, Costa, Ricardo, additional, Sia, Ying Tung, additional, Lemay, Catherine, additional, Gisbert, Alejandro, additional, Gervais, Pierre, additional, Rheault, Alain, additional, Phaneuf, Denis Carl, additional, Garg, Pallav, additional, Chow, Benjamin J. W., additional, Hessian, Renee C., additional, Beanlands, Rob S., additional, Davies, Richard F., additional, Bainey, Kevin R., additional, Cheema, Asim N., additional, Bagai, Akshay, additional, Wald, Ron, additional, Goodman, Shaun, additional, Graham, John Joseph, additional, Peterson, Mark, additional, Chow, Chi‐Ming, additional, Abramson, Beth, additional, Cheema, Asim Nazir, additional, Vakani, Mohammad Tariq, additional, Cha, James, additional, Howarth, Andrew G, additional, Wong, Graham, additional, Uxa, Amar, additional, Galiwango, Paul, additional, Kassam, Saleem, additional, Mukherjee, Ashok, additional, Ricci, A. Joseph, additional, Lam, Andy, additional, Mehta, Shamir, additional, Udell, Jacob, additional, Généreux, Philippe, additional, Hameed, Adnan, additional, Daba, Ledjalem, additional, Hueb, Whady, additional, Rezende, Paulo Cury, additional, Silva, Expedito Eustáquio Ribeiro, additional, Hueb, Alexandre Ciappina, additional, Smanio, Paola Emanuela Poggio, additional, de Quadros, Alexandre Schaan, additional, Kalil, Renato Abdala Karam, additional, da Costa Vieira, José Luiz, additional, Grossmann, Gabriel, additional, de Oliveira, Pedro Píccaro, additional, Bridi, Leonardo, additional, Savaris, Simone, additional, Vitola, João V., additional, Cerci, Rodrigo J., additional, Farias, Fabio R., additional, Fernandes, Miguel M., additional, Marin‐Neto, José Antonio, additional, Schmidt, André, additional, de Oliveira Lima Filho, Moysés, additional, Oliveira, Ricardo Mendes, additional, Chierice, João Reynaldo Abbud, additional, Polanczyk, Carísi A., additional, Furtado, Mariana V., additional, Smidt, Luis F., additional, Carvalho, Antonio Carlos, additional, Pucci, Gustavo, additional, Lyra, Flavio, additional, Junior, Alvaro Rabelo Alves, additional, Dracoulakis, Marianna D. A., additional, Lima, Rodolfo G. S. D, additional, Figueiredo, Estevao, additional, Caramori, Paulo Ricardo, additional, Tumelero, Rogerio, additional, Dall’Orto, Frederico, additional, Mesquita, Claudio T., additional, Colafranseschi, Alexandre S., additional, Oliveira, Amarino C., additional, Carvalho, Luiz A., additional, Palazzo, Isabella C., additional, Sousa, Andre S., additional, da Silva, Expedito Eustáquio Ribeiro, additional, de Barros, Pedro Gabriel Melo, additional, de Pádua Silva Baptista, Luciana, additional, Rodrigues, Marcelo Jamus, additional, de Resende, Marcos Valério Coimbra, additional, Saraiva, Jose Francisco, additional, Costantini, Costantino, additional, Demkow, Marcin, additional, Pracon, Radoslaw, additional, Kepka, Cezary, additional, Teresinska, Anna, additional, Kryczka, Karolina, additional, Henzel, Jan, additional, Solecki, Mateusz, additional, Kaczmarska, Edyta, additional, Mazurek, Tomasz, additional, Drozdz, Jaroslaw, additional, Czarniak, Bartosz, additional, Frach, Malgorzata, additional, Szymczyk, Konrad, additional, Niedzwiecka, Iwona, additional, Sobczak, Sebastian, additional, Ciurus, Tomasz, additional, Jakubowski, Piotr, additional, Misztal‐Teodorczyk, Magdalena, additional, Teodorczyk, Dawid, additional, Fratczak, Aleksandra, additional, Szkopiak, Marcin, additional, Lebioda, Patrycja, additional, Wlodarczyk, Michal, additional, Plachcinska, Anna, additional, Kusmierek, Jacek, additional, Miller, Magdalena, additional, Marciniak, Halina, additional, Wojtczak‐Soska, Karolina, additional, Luczak, Katarzyna, additional, Tarchalski, Tomasz, additional, Cichocka‐Radwan, Anna, additional, Szwed, Hanna, additional, Szulczyk, Grazyna Anna, additional, Witkowski, Adam, additional, Kukula, Krzysztof, additional, Celinska‐Spodar, Malgorzta, additional, Zalewska, Joanna, additional, Gajos, Grzegorz, additional, Bury, Krzysztof, additional, Pruszczyk, Piotr, additional, Roik, Marek, additional, Loboz‐Grudzien, Krystyna, additional, Sokalski, Leszek, additional, Brzezinska, Barbara, additional, Lesiak, Maciej, additional, Lanocha, Magdalena, additional, Reczuch, Krzysztof W., additional, Kalarus, Zbigniew, additional, Swiatkowski, Andrzej, additional, Szulik, Mariola, additional, Musial, Wlodzimierz J., additional, Bockeria, Leo, additional, Petrosyan, Karen, additional, Trifonova, Tatiana, additional, Chernyavskiy, Alexander M., additional, Kretov, Evgeniy I., additional, Grazhdankin, Igor O., additional, Bershtein, Leonid L., additional, Sayganov, Sergey A., additional, Kuzmina‐Krutetskaya, Anastasia M., additional, Zbyshevskaya, Elizaveta V., additional, Katamadze, Nana O., additional, Demchenko, Elena A., additional, Kozlov, Pavel S., additional, Kozulin, Vikentiy Y., additional, Lubinskaya, Ekaterina I., additional, Lopez‐Sendon, Jose, additional, Castro, Almudena, additional, Salicio, Elena Refoyo, additional, Guzman, Gabriela, additional, Galeote, Gabriel, additional, Valbuena, Silvia, additional, Peteiro, Jesús, additional, Martínez‐Ruíz, María Dolores, additional, Pérez‐Fernández, Ruth, additional, Cuenca‐Castillo, José J., additional, Flores‐Ríos, Xacobe, additional, Prada‐Delgado, Óscar, additional, Barge‐Caballero, Gonzalo, additional, Juanatey, Jose Ramon Gonzalez, additional, Bayarri, Miguel Souto, additional, Nuñez, Virginia Pubull, additional, Sanchez, Raymundo Ocaranza, additional, Alvarez, Belen Cid, additional, Gil, Carlos Peña, additional, Monzonis, Amparo Martinez, additional, Sionis, Alessandro, additional, Perales, Montserrat Vila, additional, Padró, Josep Maria, additional, Peñaranda, Antonio Serra, additional, Picart, Joan García, additional, Iglesias, Antonino Ginel, additional, Marimon, Xavier Garcia‐Moll, additional, Lladó, Guillem Pons, additional, Costa, Francesc Carreras, additional, Miro, Vicente, additional, Diez, Jose L., additional, Calvillo, Pilar, additional, Ortuño, F. Marin, additional, Chávarri, M. Valdés, additional, Montolliu, A. Tello, additional, Bermudez, E. Pinar, additional, De La Morena, G., additional, Blancas, Montserrat Gracida, additional, Luena, Jose Enrique Castillo, additional, Fernandez‐Aviles, Francisco, additional, Chen, Jiyan, additional, Wu, Yongjian, additional, Ma, Yitong, additional, Yang, Yining, additional, Ji, Zheng, additional, Yang, Xinchun, additional, Lin, Wenhua, additional, Zeng, Hesong, additional, Fu, Xin, additional, Yang, Bin, additional, Wang, Songtao, additional, Cheng, Gong, additional, Zhao, Yulan, additional, Fang, Xuehua, additional, Zeng, Qiutang, additional, Su, Xi, additional, Li, Qingxian, additional, Nie, Shao‐ping, additional, Yu, Qin, additional, Wang, Jian’an, additional, Zhang, Shuyang, additional, Liu, Zhenyu, additional, Perna, Gian Piero, additional, Marini, Marco, additional, Gabrielli, Gabriele, additional, Provasoli, Stefano, additional, Verna, Edoardo, additional, Monti, Lorenzo, additional, Nardi, Barbara, additional, Di Chiara, Antonio, additional, Mortara, Andrea, additional, Galvani, Marcello, additional, Ottani, Filippo, additional, Sicuro, Marco, additional, Calabro, Paolo, additional, Formisano, Tiziana, additional, Tarantini, Giuseppe, additional, Cucchini, Umberto, additional, Andres, Anto Luigi, additional, Racca, Emanuela, additional, Briguori, Carlo, additional, Amati, Roberto, additional, Vergoni, William, additional, Russo, Aldo, additional, Fanelli, Raffaele, additional, Poh, Kian‐Keong, additional, Chai, Ping, additional, Lau, Titus, additional, Loh, Joshua P., additional, Tay, Edgar L., additional, Teoh, Kristine, additional, Teo, Lynette L., additional, Ong, Ching‐Ching, additional, Wong, Raymond C., additional, Loh, Poay‐Huan, additional, Kofidis, Theodoros, additional, Chan, Wan Xian, additional, Chan, Koo Hui, additional, Foo, David, additional, Kong, Jason Loh Kwok, additional, Er, Ching Min, additional, Jafary, Fahim Haider, additional, Chua, Terrance, additional, Doerr, Rolf, additional, Stumpf, Juergen, additional, Matschke, Klaus, additional, Simonis, Gregor, additional, Kadalie, Clemens T., additional, Sechtem, Udo, additional, Ong, Peter, additional, Schulze, P. Christian, additional, Goebel, Bjoern, additional, Lenk, Karsten, additional, Nickenig, Georg, additional, Schuchlenz, Herwig, additional, Weikl, Stefan, additional, Lang, Irene Marthe, additional, Huber, Kurt, additional, Jakl‐Kotauschek, Gabriele, additional, Vertes, Andras, additional, Varga, Albert, additional, Fontos, Geza, additional, Merkely, Bela, additional, Kerecsen, Gabor, additional, Hinic, Sasa, additional, Zdravkovic, Marija, additional, Mudrenovic, Vladan, additional, Crnokrak, Bogdan, additional, Beleslin, Branko D., additional, Boskovic, Nikola N., additional, Petrovic, Marija T., additional, Dobric, Milan R., additional, Markovic, Zeljko Z., additional, Mladenovic, Ana S., additional, Cemerlic‐Adjic, Nada, additional, Davidovic, Goran, additional, Vucic, Rada, additional, Dekleva, Milica Nikola, additional, Stankovic, Goran, additional, Apostolovic, Svetlana, additional, Escobedo, Jorge, additional, Baleón‐Espinosa, Rubén, additional, Campos‐Santaolalla, Arturo S., additional, Durán‐Cortés, Elihú, additional, Flores‐Palacios, José M., additional, García‐Rincón, Andrés, additional, Jiménez‐Santos, Moisés, additional, Peñafiel, Joaquín V., additional, Ortega‐Ramírez, José A., additional, Valdespino‐Estrada, Aquiles, additional, Rosas, Erick Alexánderson, additional, Selvanayagam, Joseph B., additional, Joseph, Majo X., additional, Thambar, Suku T., additional, Beltrame, John F., additional, Hillis, Graham S., additional, Thuaire, Christophe, additional, Dutoiu, Téodora, additional, Steg, Philippe Gabriel, additional, Juliard, Jean‐Michel, additional, Slama, Michel S., additional, El Mahmoud, Rami, additional, Nicollet, Eric, additional, Goube, Pascal, additional, Barone‐Rochette, Gilles, additional, Furber, Alain, additional, Bière, Loïc, additional, Laucevicius, Aleksandras, additional, Celutkiene, Jelena, additional, Kedhi, Elvin, additional, Timmer, Jorik, additional, Hermanides, Rik, additional, Kaplan, Eliza, additional, Riezebos, Robert K., additional, Samadi, Pouneh, additional, van Dongen, Elise, additional, Niehe, Sander R., additional, Suryapranata, Harry, additional, van Vugt, Stijn, additional, Ramos, Ruben, additional, Cacela, Duarte, additional, Santana, Ana, additional, Fiarresga, Antonio, additional, Sousa, Lidia, additional, Marques, Hugo, additional, Patricio, Lino, additional, Bernanrdes, Luis, additional, Rio, Pedro, additional, Carvalho, Ramiro, additional, Ferreira, Rui, additional, Silva, Tiago, additional, Rodrigues, Ines, additional, Modas, Pedro, additional, Portugal, Guilherme, additional, Fragata, Jose, additional, Pinto, Fausto J., additional, Menezes, Miguel Nobre, additional, Lopes, Guilhermina Cantinho, additional, Almeida, Ana Gomes, additional, Silva, Pedro Canas, additional, Nobre, Angelo, additional, Francisco, Ana Rita, additional, Ferreira, Nuno, additional, Lopes, Ricardo L., additional, Guzman, Luis, additional, Figal, Julio César, additional, Méndiz, Oscar, additional, Cortés, Claudia, additional, Favaloro, Roberto René, additional, Alvarez, Carlos, additional, Courtis, Javier, additional, Zeballos, Gabriela, additional, Schiavi, Lilia, additional, Rubio, Mariano, additional, Devlin, Gerard Patrick, additional, Fisher, Raewyn, additional, Stewart, Ralph Alan Huston, additional, White, Harvey Douglas, additional, Benatar, Jocelyne, additional, Kedev, Sasko, additional, Mitevska, Irena Peovska, additional, Kostovska, Elizabeta Srbinovska, additional, Pejkov, Hristo, additional, Eggers, Kai, additional, Frostfelt, Gunnar, additional, Johnston, Nina, additional, Olsowka, Maciej, additional, Åkerblom, Axel, additional, Soveri, Inga, additional, Aspberg, Johannes, additional, Sharir, Tali, additional, Elian, Dan, additional, Kerner, Arthur, additional, Massalha, Samia, additional, Fukuda, Keiichi, additional, Kohsaka, Shun, additional, Yasuda, Satoshi, additional, Nishimura, Shigeyuki, additional, Van de Werf, Frans, additional, Claes, Kathleen, additional, Hung, Chung‐Lieh, additional, Yun, Chun‐Ho, additional, Hou, Charles Jia‐Yin, additional, Kuo, Jen‐Yuan, additional, Yeh, Hung‐I, additional, Hung, Ta‐Chuan, additional, Li, Jiun‐Yi, additional, Chien, Chen‐Yen, additional, Tsai, Cheng‐Ting, additional, Liu, Chun‐Chieh, additional, Yu, Fa‐Chang, additional, Lin, Yueh‐Hung, additional, Lan, Wei‐Ren, additional, Yen, Chih‐Hsuan, additional, Tsai, Jui‐Peng, additional, Sung, Kuo‐Tzu, additional, Ntsekhe, Mpiko, additional, Pandie, Shaheen, additional, Viljoen, Charle A., additional, De Andrade, Marianne, additional, Moccetti, Tiziano, additional, Rossi, M. Grazia, additional, Abdelhamid, Magdy, additional, Adel, Ahmed, additional, Kamal, Ahmed, additional, Mahrous, Hossam, additional, El Kaffas, Sameh, additional, El Fishawy, Hussien, additional, Pop, Calin, additional, Claudia, Matei, additional, Popescu, Bogdan A., additional, Ginghina, Carmen, additional, Deleanu, Dan, additional, Iliescu, Vlad A., additional, Al‐Mallah, Mouaz H., additional, Aljzeeri, Ahmed, additional, Najm, Hani, additional, Alghamdi, Ali, additional, Ramos, Walter Enrique Mogrovejo, additional, Kuanprasert, Srun, additional, Prommintikul, Arintaya, additional, Nawarawong, Weerachai, additional, Woragidpoonpol, Surin, additional, Tepsuwan, Thitipong, additional, Taksaudom, Noppon, additional, Rimsukcharoenchai, Chataroon, additional, Euathrongchit, Juntima, additional, Wannasopha, Yutthaphan, additional, Yamwong, Sukit, additional, Sritara, Piyamitr, additional, Aramcharoen, Suthara, additional, Meemuk, Krissada, additional, Khairuddin, Ahmad, additional, Hadi, Hafidz Abd, additional, and Yahaya, Shaiful Azmi, additional

Published
2024
Full Text
View/download PDF

30. Netarsudil monotherapy as the initial treatment for open-angle glaucoma and ocular hypertension in Indian patients: A real-world evaluation of efficacy and safety

Author

Mathur, Manoj, Ratnam, P., Saikumar, S., John, Manuel, Ravishankar, Siddharth, Dinesh, M., Chandil, Priya, Pahuja, Kishore, Cherlikar, Vidya, Wadhwani, Sunny, Bendale, Pankaj, Hazari, Ajit, Mishra, Rajesh, Deshmukh, Susheel, Achlerkar, Rahul, Shah, Devang, Hingorani, Chanda, Shah, Kaivan, Topiwala, Pratik, Jani, Sheetal, Rana, Viral, Majumdar, Nilay, Chakrabarti, Debasis, Dey, Rituparna, Halder, Debabrata, Choudhury, Sumit, Kumar, Ajeet, Das, Sasmita, Nanda, Ashok, Kumar, Vidya, Dubey, Rama, Kamdar, Gulam, Pandey, Alka, Kishanpuria, Sheetal, Srivastava, Rajat, Singh, Parul, Verma, Sunil, Sharma, Neha, and Gupta, Rajeev

Subjects
Blindness -- Risk factors -- Prevention, Glaucoma -- Development and progression -- Care and treatment, Health
Abstract

Byline: Manoj. Mathur, P. Ratnam, S. Saikumar, Manuel. John, Siddharth. Ravishankar, M. Dinesh, Priya. Chandil, Kishore. Pahuja, Vidya. Cherlikar, Sunny. Wadhwani, Pankaj. Bendale, Ajit. Hazari, Rajesh. Mishra, Susheel. Deshmukh, Rahul. [...]

Published
2023

31. Age-related cataract - Prevalence, epidemiological pattern and emerging risk factors in a cross-sectional study from Central India

Author

Sarkar, Deepayan, Sharma, Ria, Singh, Priti, Verma, Vidhya, Karkhur, Samendra, Verma, Sunil, Soni, Deepak, and Sharma, Bhavana

Subjects
Age factors in disease -- Analysis, Prevalence studies (Epidemiology) -- Analysis, Cataract -- Surgery -- Diagnosis -- Care and treatment, Health
Abstract

Byline: Deepayan. Sarkar, Ria. Sharma, Priti. Singh, Vidhya. Verma, Samendra. Karkhur, Sunil. Verma, Deepak. Soni, Bhavana. Sharma Purpose: To study the epidemiological pattern, prevalence, types, and correlates of age-related cataracts [...]

Published
2023

33. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

Author

Miller, Kathy, Cortes, Javier, Hurvitz, Sara A, Krop, Ian E, Tripathy, Debu, Verma, Sunil, Riahi, Kaveh, Reynolds, Joseph G, Wickham, Thomas J, Molnar, Istvan, and Yardley, Denise A

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Rare Diseases, Clinical Trials and Supportive Activities, Cancer, Clinical Research, Breast Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Doxorubicin, Female, Humans, Immunoconjugates, Immunotoxins, Molecular Targeted Therapy, Neoplasm Metastasis, Polyethylene Glycols, Receptor, ErbB-2, Research Design, Single-Chain Antibodies, Trastuzumab, Advanced/metastatic breast cancer, Antibody-conjugate, Cardiotoxicity, HERMIONE, Human epidermal growth factor receptor 2/HER2/Erb2, HER2-targeted liposomal doxorubicin, Immunoliposome, MM302, Receptor, erbB-2, Antibody–conjugate, MM­302, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Epidemiology
Abstract

BackgroundHuman epidermal growth factor receptor 2 (HER2)-positive breast cancer is a particularly aggressive form of the disease, and ultimately progresses in patients with metastases on standard therapies. Anthracyclines, such as doxorubicin, are an effective treatment for HER2-positive breast cancer, particularly when administered in combination with trastuzumab - however, doxorubicin-related cardiotoxicity has limited its use. Many patients are therefore never treated with anthracyclines, even upon disease progression, despite the potential for benefit. MM-302 is a novel, HER2-targeted antibody-liposomal doxorubicin conjugate that specifically targets HER2-overexpressing cells. Preclinical and Phase 1 data suggest that MM-302, as a monotherapy or in combination with trastuzumab, could be effective for managing previously treated, anthracycline-naïve, HER2-positive breast cancer, without the cardiotoxicity observed with free doxorubicin formulations.Methods/designHERMIONE is an open-label, multicenter, randomized (1:1) Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice (gemcitabine, capecitabine, or vinorelbine) plus trastuzumab planned to enroll 250 anthracycline-naïve patients with locally advanced/metastatic HER2-positive breast cancer. Key inclusion criteria are: previous treatment with trastuzumab (with or without pertuzumab) in any setting; refractory or intolerant to pertuzumab (refractory to pertuzumab defined as progression in the locally advanced or metastatic setting, or disease recurrence during or within 12 months of completing pertuzumab-containing neoadjuvant and/or adjuvant therapy); and disease progression on, or intolerant to, ado-trastuzumab emtansine for locally advanced or metastatic disease. The trial is currently being conducted at sites in the USA, Canada, and Western Europe. Treatment will be administered in 21-day cycles, and will be continued until disease progression or unacceptable toxicity. The primary endpoint is independently assessed progression-free survival (PFS). Tumor response will be assessed every 6 weeks, and defined according to RECIST v1.1. Secondary endpoints include investigator-assessed PFS, overall survival (OS), OS rates at 6 months and 1 year, objective response rates, safety and tolerability, quality of life, and the pharmacokinetic profile of MM-302 plus trastuzumab.DiscussionThe HERMIONE study will evaluate the efficacy and safety of MM-302 plus trastuzumab in patients with refractory HER2-positive advanced/metastatic breast cancer for whom there are no standard of care therapies with a proven survival advantage.Trial registrationClinicaltrials.gov identifier: NCT02213744 . Registration date: 06AUG2014.

Published
2016

34. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor‐Positive/HER2‐Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo‐Controlled, Phase III Study (PALOMA‐3)

Author

Verma, Sunil, Bartlett, Cynthia Huang, Schnell, Patrick, DeMichele, Angela M, Loi, Sherene, Ro, Jungsil, Colleoni, Marco, Iwata, Hiroji, Harbeck, Nadia, Cristofanilli, Massimo, Zhang, Ke, Thiele, Alexandra, Turner, Nicholas C, and Rugo, Hope S

Subjects
Clinical Trials and Supportive Activities, Breast Cancer, Patient Safety, Vaccine Related, Cancer, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Estradiol, Female, Fulvestrant, Humans, Neoplasm Metastasis, Piperazines, Pyridines, Receptor, ErbB-2, Receptors, Estrogen, Cyclin-dependent kinase 4, Cyclin-dependent kinase 6, Palbociclib, Neutropenia, Receptor, erbB-2, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundPalbociclib enhances endocrine therapy and improves clinical outcomes in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Because this is a new target, it is clinically important to understand palbociclib's safety profile to effectively manage toxicity and optimize clinical benefit.Materials and methodsPatients with endocrine-resistant, HR-positive/HER2-negative MBC (n = 521) were randomly assigned 2:1 to receive fulvestrant (500 mg intramuscular injection) with or without goserelin with oral palbociclib (125 mg daily; 3 weeks on/1 week off) or placebo. Safety assessments at baseline and day 1 of each cycle included blood counts on day 15 for the first 2 cycles. Hematologic toxicity was assessed by using laboratory data.ResultsA total of 517 patients were treated (palbociclib, n = 345; placebo, n = 172); median follow-up was 8.9 months. With palbociclib, neutropenia was the most common grade 3 (55%) and 4 (10%) adverse event; median times to onset and duration of grade ≥3 episodes were 16 and 7 days, respectively. Asian ethnicity and below-median neutrophil counts at baseline were significantly associated with an increased chance of developing grade 3-4 neutropenia with palbociclib. Dose modifications for grade 3-4 neutropenia had no adverse effect on progression-free survival. In the palbociclib arm, febrile neutropenia occurred in 3 (

Published
2016

35. Quantitative Evaluation of Adult Subglottic Stenosis Using Intraoperative Long-range Optical Coherence Tomography

Author

Sharma, Giriraj K, Loy, Anthony Chin, Su, Erica, Jing, Joe, Chen, Zhongping, Wong, Brian J-F, and Verma, Sunil

Subjects
Biomedical and Clinical Sciences, Ophthalmology and Optometry, Bioengineering, Biomedical Imaging, Adult, Ascorbic Acid, Female, Ferrous Compounds, Humans, Image Processing, Computer-Assisted, Imaging, Three-Dimensional, Intraoperative Care, Laryngoscopy, Laryngostenosis, Larynx, Organ Size, Tomography, Optical Coherence, Trachea, subglottic stenosis, optical coherence tomography, airway measurement, direct laryngoscopy, suspension microlaryngoscopy, Clinical Sciences, Otorhinolaryngology, Clinical sciences, Allied health and rehabilitation science
Abstract

ObjectivesTo determine the feasibility of long-range optical coherence tomography (LR-OCT) as a tool to intraoperatively image and measure the subglottis and trachea during suspension microlaryngoscopy before and after endoscopic treatment of subglottic stenosis (SGS).MethodsLong-range optical coherence tomography of the adult subglottis and trachea was performed during suspension microlaryngoscopy before and after endoscopic treatment for SGS. The anteroposterior and transverse diameters, cross-sectional area (CSA), distance from the vocal cords, and length of the SGS were measured using a MATLAB software. Pre-intervention and postintervention airway dimensions were compared. Three-dimensional volumetric airway reconstructions were generated using medical image processing software (MIMICS).ResultsIntraoperative LR-OCT imaging was performed in 3 patients undergoing endoscopic management of SGS. Statistically significant differences in mean anteroposterior diameter (P < .01), transverse diameter (P < .001), and CSA (P < .001) were noted between pre-intervention and postintervention data. Three-dimensional airway models were viewed in cross-sectional format and via virtual "fly through" bronchoscopy.ConclusionsThis is the first report of intraoperative LR-OCT of the subglottic and tracheal airway before and after surgical management of SGS in humans. Long-range optical coherence tomography offers a practical means to measure the dimensions of SGS and acquire objective data on the response to endoscopic treatment of SGS.

Published
2016

37. Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer

Author

Mackey, John R, Ramos-Vazquez, Manuel, Lipatov, Oleg, McCarthy, Nicole, Krasnozhon, Dmitriy, Semiglazov, Vladimir, Manikhas, Alexey, Gelmon, Karen A, Konecny, Gottfried E, Webster, Marc, Hegg, Roberto, Verma, Sunil, Gorbunova, Vera, Abi Gerges, Dany, Thireau, Francois, Fung, Helena, Simms, Lorinda, Buyse, Marc, Ibrahim, Ayman, and Martin, Miguel

Subjects
Cancer, Clinical Research, Clinical Trials and Supportive Activities, Breast Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Disease-Free Survival, Docetaxel, Double-Blind Method, Drug Administration Schedule, Fatigue, Febrile Neutropenia, Female, Hand-Foot Syndrome, Humans, Hypertension, Immunoglobulin G, Kaplan-Meier Estimate, Middle Aged, Neoplasm Recurrence, Local, Stomatitis, Taxoids, Treatment Outcome, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeCurrently, antiangiogenic strategies in metastatic breast cancer have demonstrated modest improvements in progression-free survival (PFS) but not improved quality or duration of survival, warranting evaluation of new agents in a placebo-controlled setting. Ramucirumab is a human immunoglobulin G1 antibody that binds vascular endothelial growth factor receptor-2 and blocks ligand-stimulated activation. The ROSE/TRIO-012 trial evaluated ramucirumab with docetaxel in unresectable, locally recurrent, or metastatic breast cancer.Patients and methodsIn this double-blind, placebo-controlled, randomized, multinational phase III trial, 1,144 patients with human epidermal growth factor receptor 2 (HER2) -negative breast cancer who had not received cytotoxic chemotherapy in the advanced setting were randomly assigned at a two-to-one ratio to receive docetaxel 75 mg/m(2) plus ramucirumab 10 mg/kg or docetaxel 75 mg/m(2) plus placebo once every 3 weeks. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria. Patients were stratified by previous taxane therapy, visceral metastasis, hormone receptor status, and geographic region. An independent data monitoring committee oversaw the trial. The primary end point was investigator-assessed PFS.ResultsMedian PFS in patients treated with ramucirumab plus docetaxel was 9.5 months, compared with 8.2 months in patients who received placebo plus docetaxel (hazard ratio [HR], 0.88; P = .077). Median overall survival was 27.3 months in patients who received ramucirumab plus docetaxel, compared with 27.2 months in patients who received placebo plus docetaxel (HR, 1.01; P = .915). Toxicities seen at significantly higher rates in patients receiving ramucirumab included fatigue, hypertension, febrile neutropenia, palmar-plantar erythrodysesthesia syndrome, and stomatitis.ConclusionAddition of ramucirumab to docetaxel in HER2-negative advanced breast cancer did not meaningfully improve important clinical outcomes.

Published
2015

38. Optical coherence tomography-based assessment of macular vessel density, retinal layer metrics and sub-foveal choroidal thickness in COVID-19 recovered patients

Author

Karkhur, Samendra, Chauhan, Khushboo, Soni, Deepak, Sharma, Bhavana, Yadav, Nikita, Banerjee, Lagnajeeta, Nyodu, Richa, and Verma, Sunil

Subjects
Eye diseases -- Risk factors -- Prevention, Coherence (Optics) -- Analysis, Eye -- Medical examination, Optical tomography -- Analysis, Health
Abstract

Byline: Samendra. Karkhur, Khushboo. Chauhan, Deepak. Soni, Bhavana. Sharma, Nikita. Yadav, Lagnajeeta. Banerjee, Richa. Nyodu, Sunil. Verma Purpose: The primary objective of the study was to assess the macular retinal [...]

Published
2023

39. Rhino-orbito-cerebral mucormycosis and its resurgence during COVID-19 pandemic: A review

Author

Karkhur, Samendra, Soni, Deepak, Chauhan, Khushboo, Sarkar, Deepayan, Gautam, Megha, Verma, Sunil, Nyodu, Richa, Yadav, Nikita, and Sharma, Bhavana

Subjects
Eye infections -- Development and progression -- Care and treatment, Practice guidelines (Medicine) -- Evaluation, Mucormycosis -- Development and progression -- Care and treatment, Health
Abstract

Byline: Samendra. Karkhur, Deepak. Soni, Khushboo. Chauhan, Deepayan. Sarkar, Megha. Gautam, Sunil. Verma, Richa. Nyodu, Nikita. Yadav, Bhavana. Sharma This study aimed to review the current literature for epidemiology, pathogenesis, [...]

Published
2023

40. Commentary: Ophthalmology training programs: Optimization of human resource to supplement clinical expertise and strengthen eye care delivery systems

Author

Singh, Priti, Jain, Nikhila, Verma, Sunil, and Sharma, Bhavana

Subjects
Eye diseases -- Development and progression -- Care and treatment, Medical personnel -- Training, Clinical competence -- Evaluation, Health
Abstract

Byline: Priti. Singh, Nikhila. Jain, Sunil. Verma, Bhavana. Sharma Preventable blindness is a significant public health concern, especially in developing countries. According to the National Blindness and Visual Impairment Survey [...]

Published
2023

41. Prevalence of hypertension among Indian adults: Results from the great India blood pressure survey

Author

Shivkumar Rao, J., Singh, B.P., Bharti, B.B., Sinha, A.K., Gupta, Kartik, Ramakrishnan, Sivasubramanian, Bhushan, Sudha, Verma, Sunil K., Bhargava, Balram, Roy, Ambuj, Bansal, Sandeep, Sood, Sanjay, Isser, H.S., Pandit, Neeraj, Nath, Ranjit K., Tyagi, Sanjay, Trehan, Vijay, Gupta, Mohit D., Girish, M.P., Ahuja, Ramandeep, Manchanda, S.C., Mohanty, Arun, Jain, Peeyush, Shrivastava, Sameer, Kalra, I.P.S., Sarang, B.S., Ratti, H.S., Sahib, G. Bala, Gupta, Rakesh, Agarwal, S.K., Amit, Goswami, K.C., Bahl, V.K., Chopra, H.K., Seth, Ashok, Zachariah, Geevar, Mohanan, P.P., Venugopal, K., Koshy, George, Nair, Tiny, Shyam, N., Roby, Anil, George, Raju, Kumar, Sudhaya, Kader, Abdul, Abraham, Mathew, Viswanathan, Sunitha, Jabir, A., Menon, Jaideep, Unni, Govindan, Mathew, Cibu, Sajeev, PB Jayagopal, Ashokan, P.K., Asharaf, Mandal, Subroto, Pancholia, A.K., Bardolei, Neil, Gupta, A.K., Das, Rupam, Aggarwal, Dinesh, Malviya, Amit, Routray, S.N., Mishra, S.S., Ali, Syed Manzor, Barward, Parag, Singh, Navreet, Tomar, Yashbir S., Chaddha, Davinder, Dani, Sameer, Vyas, Chirayu, Bhatt, Kinjal, Doshi, Shrenik, Wander, G.S., Gupta, Satish, Meena, Chandra Bhan, Sateesh, Santosh, Senguttuvan, Nagendra Boopathy, Subramanyam, Geetha Subramanyam, Muruganandam, Ajit Mullasari, Sethi, Rishi, Narain, Varun, Saran, R.K., Jain, Dharmendra, Jain, Praveen, Kumar, Sudeep, Goel, P.K., Roy, Debabatra, Datta, Sibananda, Ganguly, Kajal, Das, M.K., Kumar, Soumitra, Banerjee, Sarat Chandra Amal, Guha, Santanu, Deb, P.K., Mani, Kalaivani, Kakar, Tanya Singh, Kidambi, Bharathraj, Kothari, Shyam S., Gupta, Rajeev, Subramanyam, Geetha, Das, Mrinal K., Chandra, Sarat, Banerjee, Amal, and Deedwania, Prakash

Published
2019
Full Text
View/download PDF

42. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Author

Bouzid, Kamel, Campone, Mario, Coudert, Bruno, Nowecki, Zbigniew, Errihani, Hassan, Dalenc, Florence, Ferreira, Ana, Mano, Max, Ricci, Francesco, Kalofonos, Haralabos, Andreetta, Claudia, Montemurro, Filippo, Barrett, Sophie, Zhang, Qingyuan, Mavroudis, Dimitris, Matus, Juan, Beato, Carlos, Hu, Xichun, Gaafar, Rabab, Abdel Azeem, Hamdy, Perrin, Christophe, Ettl, Johannes, Lang, Istvan, Verma, Sunil, Li, Huiping, Brain, Etienne, Hoffmann, Oliver, Cariello, Anna, Tondini, Carlo, Altwegeiri, Taher, Loman, Niklas, Lux, Michael, Frassoldati, Antonio, Aziz, Zeba, Salas, Fernando, Streb, Joanna, Wronski, Andrzej, Menjón Beltrán, Salomón, Cicin, Irfan, Schmid, Peter, Laing, Robert, Tong, Zhongsheng, Boer, Katalin, Juhasz, Balazs, Gianni, Luca, Curigliano, Giuseppe, Juarez, Alejandro, Susnjar, Snezana, Matos, Erika, Uslu, Ruchan, Wildiers, Hans, Cruz, Marcelo, Bourgeois, Hugues, von Schumann, Raquel, Stemmer, Salomón, Vásquez, Flavia Morales, Dominguez, Adriana, Wojtukiewicz, Marek, Trifunovic, Jasna, Illarramendi, Jose Juan, Garcia, Laura, Peron, Yann Izarzugaza, Echarri, Maria Jose, Voitko, Natliia, Wheatley, Duncan, Waters, Simon, De Boer, Richard, Jerusalem, Guy, Cocquyt, Véronique, Barrios, Carlos, Panasci, Lawrence, Mattson, Johanna, Tanner, Minna, Gozy, Michel, Vasilopoulos, Georgios, Revesz, Janos, Latini, Luciano, Gridelli, Cesare, Lazaro, Jesus, Gonzalez, Antonio, Barnadas Molins, Agusti, Martinez, Eduardo, Alarcón, Jesús, Arance, Ana, Klint, Leif, Kovalyov, Oleksiy, Baird, Richard, Yeo, Belinda, McCarthy, Nicole, Greil, Richard, Wang, Shusen, Artignan, Xavier, Augereau, Paule, Juhasz-Boess, Ingolf, Ngan, Roger, Goldberg, Hadassah, Di Costanzo, Francesco, Ferraù, Francesco, Aleknavicius, Eduardas, Rashid, Kamran, Costa, Luís, Angel Garcia, Jose, de la Cruz, Luis Ruiz, López López, Rafael, Del Val, Olga, Ozyilkan, Ozgur, Azribi, Fathi, Verrill, Mark, Turner, Nicholas, Beith, Jane, Petzer, Andreas, Andrade, Jurandyr, Bernstein, Vanessa, Rayson, Daniel, Saad Eldin, Ibtessam, Achille, Mihaëla, Mueller, Volkmar, Gennari, Alessandra, Cascinu, Stefano, Ghosn, Marwan, El-Saghir, Nagi, Van den Bosch, Joan, Oosterkamp, Rianne, Kukulska, Monika, Pelaez, Ignacio, Hernandez, Carolina, del Mar Gordon, Maria, Dalmau, Elsa, Alonso, Jose Luis, Aksoy, Sercan, Coskun, Hasan Senol, Shparyk, Yaroslav, Varughese, Mohini, Panwar, Udaiveer, Barraclough, Lisa, Levitt, Nicola, Hicks, Jonathan, Rigg, Anna, Allen, Mark, Castillo, Cecila, Fein, Luis Enrique, Stuart-Harris, Robin, Singer, Christian, Stoeger, Herbert, Smiljanic, Sasha, Feng, Jifeng, Cedeño, Miguel, Berdah, Jean Francois, Orfeuvre, Hubert, Goncalves, Anthony, Grischke, Eva-Maria, Simon, Eike, Wagner, Steffen, Efremidou, Anna, Papazisis, Konstantinos, Evron, Ella, Inbar, Moshe, Baruch, Noa Ben, Geffen, David, Karminsky, Natalya, Ruggeri, Enzo Maria, Luigi, Cavanna, Grasso, Donatella, Juozaityte, Elona, Rafael Rodriguez Cid, Jeronimo, Roerdink, Henk, Siddiqi, Neelum, Passos Coelho, José Luís, Garre, Elisa Garcia, Garcia, Andres, Martínez Jañez, Noelia, Lopez Ceballos, Maria Helena, Mele, Mireia, García, María, Arcediano, Alberto, McAdam, Karen, Perren, Timothy, Taylor, Wendy, Humphreys, Alison, Vera, Raul, Kaen, Luis Alberto, Steger, Günther, Andel, Johannes, de Grève, Jacques, Huizing, Manon, Hegg, Roberto, Joy, Anil, Sehdev, Sandeep, Kütner, Riina, Ruohola, Johanna, Dohollou, Nadine, Grosjean, Jessica, Laplaige, Philippe, Largillier, Rémy, Martin, Philippe, Pottier, Virginie, Alexandre, Jerome, Christensen, Bernd, Zahm, Dirk-Michael, Khandan, Fariba, Lueck, Hans-Joachim, Fountzilas, Georgios, Fried, Georgeta, Giacobino, Alice, Bonetti, Andrea, Guerra, Yanin Chavarri, Van Warmerdam, Laurens, Van der Velden, Annette, Vrijaldenhoven, Suzan, de Jongh, Felix, Cavero, Milagros, Andres Conejero, Raquel, Murias, Adolfo, Saura, Salvador, Oltra, Amparo, Redondo, Andres, Ribelles, Nuria, Bachmeier, Kilian, Joffe, Johnathan, Chakraborti, Prabir, Beresford, Mark, Butt, Mohammad, Poole, Christopher, Yordi, Gassan, Woodward, Natasha, Amorim, Gilberto, Califaretti, Nadia, Fox, Susan, Robidoux, Andre, Li, NanLi, Li, Nenxiao, Jiang, Jun, Soria, Tannia, Padrik, Peeter, Saarni, Outi, Genet, Dominique, Catala, Stéphanie, Barletta, Hugues, Teixeira, Luis, Facchini, Thomas, Hesse, Tobias, Kühn, Thorsten, Ober, Angelika, Repp, Roland, Schroeder, Willibald, Pectasides, Dimitrios, Bodoky, Gyorgy, Kahan, Zsuzsanna, Jiveliouk, Irina, Rosengarten, Ora, Alabiso, Oscar, Perez, Mario, Van de Wouw, Yes, Smok-Kalwat, Jolanta, Damasceno, Margarida, Sousa, Gabriela, Abulkhair, Omalkhair, Antón Torres, Antonio, Martinez, Maria Purificación, Garcia Mata, Jesús, Jesús Florián Jerico, Marta Santisteban, Llombart, Antonio, Sanchez, Rosa, Torrego, Juan Carlos, Garate, Clara Olier, Rodriguez, Cesar, Llorente, Rosa, de Prado, Diego Soto, Cortés, Javier, Llorca, Cristina, Galán, Antonio, Viñas Villaro, Gemma, Narbe, Ulrik, Bjömeklett, Helena Granstam, Westwell, Sarah, Newby, Jackie, Jafri, Mariam, Rodríguez, Robinson, Alonso, Isabel, Bachelot, T., Ciruelos, E., Schneeweiss, A., Puglisi, F., Peretz-Yablonski, T., Bondarenko, I., Paluch-Shimon, S., Wardley, A., Merot, J.-L., du Toit, Y., Easton, V., Lindegger, N., and Miles, D.

Published
2019
Full Text
View/download PDF

46. Studies on the signalling of the small GTPase Rap1

Author

Verma, Sunil Kumar

Subjects
616.994
Abstract

RaplA (Krev-l) is a member of the Ras superfamily of small GTP-binding proteins and has highest homology to Ras. Rapl behaves as an antagonist of oncogenic K-Ras activity in NIH3T3 cells and of polyoma middle-T antigen in Rat-2 cells. It inhibits transformation of human prostate cancer cells, hamster pancreatic adenocarcinoma cells and of ethylcarbamate induced lung adenomas in transgenic mice. However, it does not prevent Ras induced transformation in human HT1080, EJ30 or SW48 cells. Rapl also plays a critical role in regulation of normal morphogenesis in the eye disk and the ovary during embryo development. Recently, Rapl has been implicated in integrin-mediated . adhesion through RapL and modulation of the actin cytoskeleton through RIAM. The downstream effectors through which Rapl mediates its diverse effects are largely unknown. Screening the human genome based upon structural and functional information from the known effectors of Rapl such as RapL, RaIGDS, RIAM and Kritl, a series of potential effectors of Rapl have been identified. Using classical and modem biochemical approaches, it has been established that RASSFlA, a well-known tumour suppressor of human carcinogenesis, is a novel effector of RaplA - linking RaplA to microtubules. Moreover, Rapl association influences the effect of RASSFIA on microtubule behaviour. It is shown that interaction between RASSFIA and RaplA is modulated by RASSFIA phosphorylation. In silica analyses on RASSFIA predicted various putative phosphorylation sites and associated protein kinases within and outside the RA domain of RASSFIA. The sites S197 and S203 within the RA domain of RASSFIA were established as novel PKC phosphorylation sites by in vitro and in vivo assays. These two sites were, however, not responsible for the regulated interaction of RASSFIA with RaplA. This study provides important new insights into the signalling of RaplA indicating that regulated association with RASSFIA links RaplA to microtubules and that the RaplA-RASSFIA interaction plays a role in microtubule dynamics.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results